Published in Medical Letter on the CDC and FDA, November 30th, 2003
The company reported record quarterly sales for Hectorol (doxercalciferol) of $8.1 million, compared to Hectorol sales of $5.4 million for the first quarter of 2003, representing a 50% increase in the first quarter of 2004 compared with the same period in 2003.
The net loss for the first quarter of 2004 was $2.1 million, or $0.15 per common share, compared with a net loss for the first quarter of 2003 of $1.6 million, or $0.12 per common share. The company ended the first quarter of 2004 with a total of $14.2 million in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA